Sars Cov2 Anti Rbd Spike Antibody Apc

SARS-CoV2 Spike RBD Antibody

MBS669476-0025mg 0.025mg
EUR 220

Human IgG antibody Laboratories manufactures the sars cov2 anti rbd spike antibody apc reagents distributed by Genprice. The Sars Cov2 Anti Rbd Spike Antibody Apc reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Antibody. Other Sars products are available in stock. Specificity: Sars Category: Cov2 Group: Anti Rbd

Anti-SARS CoV2 Spike RBD Antibody (Clone: ABM5H1.1E4)

0.1mg
EUR 445

Anti-SARS CoV2 Spike RBD Antibody (Clone: ABM5H1.1E4)

5x0.1mg
EUR 1990

Anti-SARS CoV2 Spike RBD Antibody (Clone: ABM1H9.1E6)

0.025mg
EUR 225

Anti-SARS CoV2 Spike RBD Antibody (Clone: ABM1H9.1E6)

0.1mg
EUR 445

Anti-SARS CoV2 Spike RBD Antibody (Clone: ABM1H9.1E6)

5x0.1mg
EUR 1990

Anti-SARS CoV2 Spike RBD Antibody (Clone: ABM6G1.1A2)

0.025mg
EUR 225

Anti-SARS CoV2 Spike RBD Antibody (Clone: ABM6G1.1A2)

0.1mg
EUR 445

Anti Rbd information

SARS CoV2 Spike S1 Antibody (Clone: ABM1G2.1F7)

MBS669595-01mg 0.1mg
EUR 445

SARS CoV2 Spike S1 Antibody (Clone: ABM1G2.1F7)

MBS669595-5x01mg 5x0.1mg
EUR 1990

Anti-SARS CoV2 Spike RBD Antibody (Clone: ABM5D1.1E8) Biotin Conjugated

MBS669602-01mg 0.1mg
EUR 445

Anti-SARS CoV2 Spike RBD Antibody (Clone: ABM5D1.1E8) Biotin Conjugated

MBS669602-5x01mg 5x0.1mg
EUR 1990

SARS CoV2 Spike S1 Antibody (Clone: ABM3D6.1G6)(13-33aa)

MBS669600-0025mg 0.025mg
EUR 225

SARS CoV2 Spike S1 Antibody (Clone: ABM3D6.1G6)(13-33aa)

MBS669600-01mg 0.1mg
EUR 445

SARS CoV2 Spike S1 Antibody (Clone: ABM3D6.1G6)(13-33aa)

MBS669600-5x01mg 5x0.1mg
EUR 1990

SARS CoV2 Spike S1 Antibody (Clone: ABM4A10.1D3)(239-257aa)

MBS669599-0025mg 0.025mg
EUR 225

SARS CoV2 Spike S1 Antibody (Clone: ABM4A10.1D3)(239-257aa)

MBS669599-01mg 0.1mg
EUR 445

SARS CoV2 Spike S1 Antibody (Clone: ABM4A10.1D3)(239-257aa)

MBS669599-5x01mg 5x0.1mg
EUR 1990

SARS-CoV-2 (COVID-19) Spike RBD Antibody

9087-002mg 0.02 mg
EUR 229.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody

9087-01mg 0.1 mg
EUR 594.26
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody

MBS154650-01mg 0.1mg
EUR 500

SARS-CoV-2 (COVID-19) Spike RBD Antibody

MBS154650-5x01mg 5x0.1mg
EUR 2230

SARS-CoV-2 (COVID-19) Spike RBD Antibody (biotin)

9087-biotin-002mg 0.02 mg
EUR 229.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody (biotin)

9087-biotin-01mg 0.1 mg
EUR 594.26
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody (biotin)

MBS154680-01mg 0.1mg
EUR 500